All results

9 results for randomized phase iii trial evaluating pathologic complete response rates patients

• Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Comp

  The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who…

  Ages

  18 Years - N/A

  Sexes

  All

• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cance

  This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment…

  Ages

  18 Years - N/A

  Sexes

  All

• Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy for Limited mCRC(ERASur)

  This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer…

  Ages

  18 Years - N/A

  Sexes

  All

• mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Tx of Metastatic HER2- GE Adendocarcinoma

  This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil,…

  Ages

  18 Years - N/A

  Sexes

  All

• Immunotherapy for Patients With Advanced Kidney Cancer, The PDIGREE Study

  This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and…

  Ages

  18 Years - N/A

  Sexes

  All

• Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adol

  This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical [haplo]) versus matched unrelated…

  Ages

  6 Months - 21 Years

  Sexes

  All

• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mix

  This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia…

  Ages

  1 Year - 25 Years

  Sexes

  All

• Genomic-Risk Stratified Txs for Unfavorable Intermediate Risk Prostate Cancer (Guidance)

  This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk)…

  Ages

  18 Years - N/A

  Sexes

  Male

• Testing Triapine w/ Targeted Radiation-based LU177 vs Lu177 alone in pts w/ metastatic NETs

  This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking…

  Ages

  18 Years - N/A

  Sexes

  All